Key Highlights

  • GRAIL shares are trading at $113.74 in pre-market activity, up 4.81% from Tuesday's close of $108.52.
  • An FDA advisory panel voted unanimously in support of Galleri's safety and split 6 to 4 in favor of its effectiveness.
  • On the overall benefit-risk profile, seven panel members voted that Galleri's benefits outweigh its risks, two voted against and one abstained.
  • Galleri has detected approximately four to seven times more cancers than standard screening alone across clinical studies, according to the company.

FDA Panel Backs Galleri's Safety and Benefit-Risk Profile

GRAIL (NASDAQ:GRAL) shares are trading higher pre-market after an FDA advisory panel voted favorably on its Galleri multi-cancer early detection blood test, moving the product a step closer to formal regulatory approval. The 10-member Molecular and Clinical Genetics Devices Panel voted unanimously in support of Galleri's safety, split 6 to 4 in favor of its effectiveness, and on the broader benefit-risk question, seven members said the test's benefits outweigh its risks against two who disagreed and one who abstained.

A Test Designed to Catch Cancer Before Symptoms Appear

Galleri is designed to detect cancer before symptoms appear, including cancers for which no recommended screening test currently exists, by identifying DNA fragments released by tumor cells into the bloodstream and analyzing their methylation patterns. The company said Galleri is supported by large interventional and randomized controlled studies, including FDA-authorized investigational device exemption studies in North America and a landmark trial in England, and has detected roughly four to seven times more cancers than standard screening alone, with most identified at earlier, more treatable stages.

Already Commercial, but Formal Approval Could Widen Adoption

GRAIL is a commercial-stage healthcare company headquartered in Menlo Park, California, that has sold over 595,000 Galleri tests since launching it as a laboratory-developed test in the U.S. in mid-2021, with second-quarter screening Revenue rising to $42.6 million from $34.3 million a year earlier. While the test is already commercially available, formal FDA approval would grant official regulatory authorization and could pave the way for broader adoption among healthcare providers, payors and other channels, with a final decision expected in the coming months.